Rexgenero's Phase III cell therapy trials enter critical phase
Privately-owned UK-based regenerative medicine company Rexgenero has provided an update on its Phase III studies of REX-001 to treat critical limb ischemia (CLI) in diabetes.
The autologous cell therapy is now being tested at 12 of 25 planned trial sites across Europe, with additional hospitals expected to be initiated by the end of the year.
REX-001 consists of bone marrow-derived white blood cells extracted from the patient and has shown efficacy in 80% of patients in Phase II and I/II studies. Rexgenero is planning to treat 138 patients in the two SALAMANDER trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze